USPTO grant strengthens Alterity’s IP position and opens a path for ATH434 into Parkinson’s disease investment.

THPharm already has a drug in late-stage trials. Now it’s using AI to work backwards and find out what else that drug might ...

Longevity is becoming big business, but the science, standards and clinical practices needed to guide the field are still ...

One-year trial results show most patients kept off GLP-1-induced weight loss after a single endoscopic procedure.

Fresh NIH funding backs an iPSC-and-AI push to find drugs for Duchenne cardiomyopathy without relying on mouse models that ...

AstronauTx has exercised its Saniona option, advancing a sleep-focused neurodegeneration candidate toward IND-enabling ...

Nature Medicine publication and late-breaking data put ImmunoBrain’s checkpoint immunotherapy and its clean safety profile in ...

Seven months after ditching paper screening for Creyos, Claremedica is catching over 90% of new dementia cases at the earliest stage.

NeuroQuant clearance automates amyloid quantification for Alzheimer’s imaging, trading radiologist’s judgment call for ...

Self-contracting myografts improved muscle, bone and metabolic measures in aging mice – without requiring the animals to ...

Health-testing company pairs its member data with NYU Grossman’s clinical expertise to try to catch diseases before symptoms ...

Oligonucleotide drug slows Alzheimer’s decline across every dose tested in Phase 2 and reframes the field’s central ...